EUVIMEDEUVIMED entdecken
Crossref

Preclinical Evaluation of 68 Ga-Labeled SL1 Aptamer for c-Met Targeted PET Imaging

Xuwei Liu, Yamei Chen, Fengsheng Zhang, Fengshuang Qiu, Xiaoping Xu, Jianping Zhang, Simin He, Ding Ding iD, Weihong Tan, Shaoli Song iD

Molecular Pharmaceutics · 03.03.2025 · 22 (3) · 1615-1623

DOI: 10.1021/acs.molpharmaceut.4c01344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 11.02.2025. Verfasst von Xuwei Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Gallium Radioisotopes, Aptamers, Nucleotide, Radiopharmaceuticals. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Science and Technology Commission of Shanghai Municipality, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tyrosine protein kinase c-Met, encoded by the Met gene, is a membrane-associated receptor tyrosine kinase that is often aberrantly expressed in a wide range of tumors. The development of imaging probes specifically targeting c-Met is critical for improving cancer diagnostics. In this study, we successfully designed and fabricated an aptamer molecular imaging probe ([68Ga]Ga-NOTA-SL1) with high radiochemical purity (RCP), good stability in vitro, and high affinity for c-Met expressed tumors. As shown by the micro-PET/CT scanning, [68Ga]Ga-NOTA-SL1 efficiently imaged tumor models with varying c-Met expression. The quantitative analysis of micro-PET/CT showed tumor uptake of [68Ga]Ga-NOTA-SL1 in the HCC827 tumor models (30 min, 2.93 ± 0.64%ID/g; 60 min, 2.03 ± 0.67%ID/g; 90 min, 1.63 ± 0.61%ID/g), PC-9 tumor models (30 min, 2.1 ± 0.72%ID/g; 60 min, 1.7 ± 0.56%ID/g; 90 min, 1.33 ± 0.38%ID/g), and HCT116 tumor models (30 min, 1.4 ± 0.17%ID/g; 60 min, 1.23 ± 0.15%ID/g; 90 min, 0.97 ± 0.21%ID/g). The results of immunohistochemistry (IHC) further confirmed the targeting ability of [68Ga]Ga-NOTA-SL1 to c-Met from a molecular pathological perspective. The probe effectively imaged c-Met-positive tumors and demonstrated a favorable metabolism profile and targeting performance in non-small cell lung cancer (NSCLC) or colorectal cancer tumor models. Consequently, this probe shows promise as an imaging agent capable of providing valuable diagnostic insights into tumors with aberrant c-Met expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-metGallium RadioisotopesAptamers, NucleotideRadiopharmaceuticalsPositron-Emission TomographyHumansAnimalsMiceCell Line, TumorPositron Emission Tomography Computed TomographyTissue DistributionMice, NudeFemale

Stichwörter der Autor:innen

aptamerc-Metmolecular imagingtargeted imaging

Substanzen

Proto-Oncogene Proteins c-metGallium RadioisotopesAptamers, NucleotideRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China.
  • Department of Oncology, Shanghai Medical College and Center for Biomedical Imaging, Fudan University, Shanghai 200032, P. R. China.
  • Center for Biomedical Imaging, Fudan University, Shanghai 200032, China.
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai 200032, P. R. China.
  • Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai 200433, China.
  • Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Shanghai 201315, China.

ORCID-Profile: Ding Ding, Shaoli Song

Förderung

  • National Key Research and Development Program of China
  • Science and Technology Commission of Shanghai Municipality
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Liu, X., Chen, Y., Zhang, F., Qiu, F., Xu, X., Zhang, J., He, S., Ding, D., Tan, W., & Song, S. (2025). Preclinical Evaluation of 68 Ga-Labeled SL1 Aptamer for c-Met Targeted PET Imaging. Molecular Pharmaceutics, 22(3), 1615-1623. https://doi.org/10.1021/acs.molpharmaceut.4c01344

Vancouver

Liu X, Chen Y, Zhang F, Qiu F, Xu X, Zhang J, et al. Preclinical Evaluation of 68 Ga-Labeled SL1 Aptamer for c-Met Targeted PET Imaging. Molecular Pharmaceutics. 2025;22(3):1615-1623. doi:10.1021/acs.molpharmaceut.4c01344

BibTeX
@article{Liu2025,
  author = {Liu, Xuwei and Chen, Yamei and Zhang, Fengsheng and Qiu, Fengshuang and Xu, Xiaoping and Zhang, Jianping and He, Simin and Ding, Ding and Tan, Weihong and Song, Shaoli},
  title = {Preclinical Evaluation of 68 Ga-Labeled SL1 Aptamer for c-Met Targeted PET Imaging},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {3},
  pages = {1615--1623},
  doi = {10.1021/acs.molpharmaceut.4c01344}
}
Kostenlos starten →